Cisplatin‐induced nephrotoxicity in an outpatient setting

Pharmacotherapy - Tập 41 Số 2 - Trang 184-190 - 2021
Carly V. Burns1, Stephanie B. Edwin1, Susan Szpunar2, Jason Forman1
1Department of Pharmacy, Ascension St. John Hospital, Detroit, MI, USA
2Department of Medical Education, Ascension St. John Hospital, Detroit, MI, USA

Tóm tắt

AbstractBackgroundThe use of cisplatin is limited by the development of nephrotoxicity, with an incidence approaching 30%. It is unclear if a risk prediction score can effectively predict the development of nephrotoxicity throughout all cycles of cisplatin therapy among outpatients.MethodsRetrospective, observational study evaluating adult patients receiving cisplatin in outpatient infusion centers from January 2009 to November 2019 (n = 186). A risk prediction score consisting of patient age, cisplatin dose, hypertension, and serum albumin was calculated to predict the risk of cisplatin‐induced nephrotoxicity.ResultsThe incidence of nephrotoxicity was 23.7% overall, with 8.1% of patients developing cisplatin‐induced nephrotoxicity after the first dose. Patients who developed nephrotoxicity had a higher mean risk prediction score compared to patients who did not have nephrotoxicity (4.0 ± 2.0 versus 2.9 ± 2.1, p = 0.004, respectively). Multivariate logistic regression demonstrated each 1‐point increase in the risk prediction score increased the odds of nephrotoxicity by 26.5% (OR: 1.27; 95% CI: 1.02–1.57, p = 0.034). Presence of diabetes mellitus increased the odds of cisplatin‐induced nephrotoxicity (OR 3.66; 95% CI: 1.43–9.33, p = 0.007), whereas receipt of greater than or equal to 1 liter of 0.9% sodium chloride was protective, decreasing the odds of developing nephrotoxicity by 25%.ConclusionBy identifying patients at the highest risk of cisplatin‐induced nephrotoxicity, providers can individualize risk reduction strategies. The use of a risk prediction model successfully predicted the risk of nephrotoxicity throughout all cycles of cisplatin in an outpatient setting.

Từ khóa


Tài liệu tham khảo

10.1007/s40620-017-0392-z

10.13005/bpj/1608

10.1016/0277-5379(89)90006-0

10.1007/BF00306754

10.1038/sj.ki.5002786

10.1345/aph.1Q333

10.1177/1078155216656927

2015, Cisplatin [package insert]

10.1007/s10157-016-1327-z

10.1200/JCO.2017.75.7161

10.1634/theoncologist.2016-0319

National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology.https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed September 20 2019.

Al‐Sarraf M, 1982, Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study, Cancer Treat Rep, 66, 31

10.1007/s00204-012-0821-7

10.1111/jcpt.12781

10.1159/000180580

Common Terminology Criteria for Adverse Events (CTCAE).Cancer Therapy Evaluation Program (CTEP).https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40. Accessed October 1 2019.

10.1093/jjco/hyt128

10.1007/s00280-003-0620-1

10.1080/1120009X.2020.1713507

Ashrafi F, 2017, Effect of short hydration on cisplatin‐induced nephrotoxicity in cancer patients: a retrospective study, Int J Hematol Stem Cell Res, 11, 263

10.1093/jjco/28.3.168

10.1345/aph.1Q333

Thông tin
Thông tin xuất bản

Pharmacotherapy

Tập 41 Số 2

184-190

Thông tin tác giả